Depo-Provera Settlement Amounts 2026: Payout Tiers and Case Value
Depo-Provera settlement amounts have not yet been established through a global court-approved settlement program. Any current payout figures are projections that may help organize claim-value factors—not confirmed averages, offers or guaranteed compensation.
As of the August 3, 2026 federal MDL report, 6,294 actions were pending in Depo-Provera MDL 3140, with 6,394 historical actions. The court’s June 23, 2026 order addressed how preemption and Rule 702 rulings apply across individual actions, and the court held a Rule 702 motions hearing on July 27, 2026.
Settlement status: On June 15, 2026 leadership counsel announced a settlement resolving a majority of claims in MDL 3140 and related New York litigation, and on July 21, 2026 the parties signed a private Master Settlement Agreement. The parties estimated that roughly 80% of MDL plaintiffs would be eligible under it. CMO No. 13 appointed BrownGreer PLC as Settlement Administrator on August 5, 2026. Registration is expected to be completed in November 2026, with payments expected to begin rolling out by Q1 2027.
Important: the Master Settlement Agreement is private. Its eligibility criteria and claimant-specific payout matrix have not been published, and no court-approved public payout matrix exists. Every range on this page is a TortAdvisor editorial estimate built from comparable litigation, not an official settlement value, and no outcome is promised or guaranteed.
Latest Depo-Provera Settlement Amounts and MDL 3140 Status
Federal Depo-Provera product-liability cases are centralized in MDL 3140 before Judge M. Casey Rodgers in the U.S. District Court for the Northern District of Florida. The August 3, 2026 JPML report listed 6,294 pending actions and 6,394 historical actions.
Depo-Provera Settlement Amounts: Confirmed Facts vs. Projections
A trustworthy settlement-amount page should separate verified litigation facts from valuation modeling. This distinction is especially important while the settlement program is still being administered and its terms remain private.
What Is Confirmed
- MDL 3140 is active in the Northern District of Florida.
- The August 3, 2026 JPML report listed 6,294 pending actions and 6,394 historical actions.
- On June 15, 2026 leadership counsel announced a settlement of a majority of claims in MDL 3140 and related New York litigation.
- The parties signed a private Master Settlement Agreement on July 21, 2026 and estimated that roughly 80% of MDL plaintiffs would be eligible under it.
- CMO No. 13 appointed BrownGreer PLC as Settlement Administrator on August 5, 2026.
- Registration is expected to be completed in November 2026, with payments expected to begin rolling out by Q1 2027.
- Federal prescribing information includes a meningioma warning and monitoring language.
- The litigation involves threshold proof of use and injury, expert evidence and individual case development.
What Is Not Yet Known
- The Master Settlement Agreement is private, so no aggregate settlement figure has been made public.
- The MSA eligibility criteria and the claimant-specific payout matrix have not been released.
- No court-approved injury tiers or point matrix have been published.
- No reliable “average payout” exists for MDL 3140.
- Individual eligibility determinations, deductions and lien resolution remain unknown, and projected registration and payment dates can move.
Projected Depo-Provera Settlement Amounts by Injury Tier
The ranges below are illustrative valuation models based on injury severity, treatment burden, permanency, proof of Depo-Provera use and documented damages. They are not official settlement offers or predictions.
Severe or Catastrophic Claim
- Recurrent, aggressive or surgically complex meningioma
- Multiple procedures, radiation or permanent neurological injury
- Major disability, future-care needs or substantial lost earning capacity
- Strong product-use, diagnosis and causation documentation
Surgery or Moderate Impact
- One significant surgery or extended treatment
- Persistent symptoms, recovery limitations or meaningful wage loss
- Documented injection history and consistent medical timeline
- Moderate future monitoring or impairment
Lower Treatment Burden
- Watch-and-wait monitoring or limited symptoms
- No surgery or comparatively limited medical expense
- Shorter or less complete documented use history
- Lower economic loss or disputed causation factors
How TortAdvisor Estimates Depo-Provera Settlement Amounts
Because the Master Settlement Agreement in MDL 3140 is private and no payout matrix has been published, TortAdvisor’s ranges are planning estimates rather than historical averages. We organize the same categories that commonly influence mass-tort valuation while clearly labeling the limits of the model.
Injury Severity
Tumor size, location, recurrence, neurological effects, surgery, radiation and prognosis.
Proof of Use
Injection records, pharmacy records, clinic records, insurance data and duration of use.
Economic Loss
Medical expenses, lost wages, reduced earning capacity, disability and future-care needs.
Litigation Risk
Causation evidence, preemption rulings, expert admissibility, jurisdiction and filing deadlines.
Depo-Provera Settlement Amounts by Claim Profile
| Claim Profile | Illustrative Range | Factors That May Raise Value | Factors That May Reduce Value |
|---|---|---|---|
| Monitoring / lower symptom burden | $100,000–$300,000 | Long documented use, clear diagnosis timing, ongoing surveillance and meaningful out-of-pocket costs. | No treatment, incomplete use records, competing risk factors or limitations problems. |
| Surgery / moderate impairment | $300,000–$750,000 | Craniotomy, extended recovery, persistent symptoms, wage loss and strong pharmacy records. | Good recovery, limited economic loss, short use duration or disputed product identity. |
| Recurrent / severe impairment | $750,000–$1.5 million+ | Multiple surgeries, radiation, cognitive or neurological disability, future care and major income loss. | Causation disputes, alternative causes, evidentiary gaps or state-law defenses. |
| Wrongful death / catastrophic loss | Case-specific; potentially above severe-injury tier | Strong medical causation, dependency loss, funeral costs and substantial lifetime economic loss. | Standing disputes, causation disputes, statutory damage limits or expired deadlines. |
Who May Qualify for Depo-Provera Settlement Amounts?
Eligibility is not determined by a settlement calculator alone. A lawyer must review product use, diagnosis, timing, defendants, state law and available evidence.
Common Screening Factors
- Use of Depo-Provera or injectable medroxyprogesterone acetate
- Diagnosis of an intracranial meningioma after or during use
- Medical imaging, pathology or neurology documentation
- Pharmacy, clinic, OB/GYN, insurance or injection records
- A claim that remains within the applicable filing period
Factors Requiring Closer Review
- Generic product use or uncertain manufacturer identification
- Incomplete injection records or uncertain treatment dates
- Meningioma diagnosis before Depo-Provera exposure
- Prior release, bankruptcy claim or settlement affecting rights
- Other medical or legal causation issues
Read the full Depo-Provera lawsuit guide for litigation background, alleged failure-to-warn claims and eligibility details.
Factors That May Increase or Reduce Depo-Provera Settlement Amounts
Duration and Frequency of Use
Longer and better-documented injection histories may strengthen proof of exposure, but duration alone does not establish causation.
Tumor Severity and Location
Tumor location, size, recurrence and effects on vision, cognition, balance, speech or other neurological functions may influence damages.
Treatment Intensity
Craniotomy, radiation, hospitalization, rehabilitation and ongoing monitoring can increase documented medical damages.
Permanent Impairment
Long-term disability, cognitive changes, seizures, loss of independence and future-care needs may materially affect valuation.
Economic Damages
Past and future medical bills, lost earnings, reduced earning capacity, travel and caregiving costs require documentation.
Legal and Scientific Proof
Product identification, diagnosis timing, expert testimony, preemption issues and applicable state law can strengthen or reduce a claim.
Evidence Supporting Depo-Provera Settlement Amounts
Product-Use Records
- Pharmacy and prescription records
- OB/GYN or clinic injection logs
- Insurance explanation-of-benefits records
- Dates, dosage and duration of injections
Medical Records
- MRI and CT imaging
- Pathology and operative reports
- Neurology and neurosurgery notes
- Radiation, rehabilitation and follow-up records
Damages Documentation
- Medical bills and insurance statements
- Wage and employment records
- Disability and future-care evidence
- Travel, caregiving and household-service costs
Filing Deadlines for Depo-Provera Settlement Amount Claims
Filing deadlines can depend on the state, date of diagnosis, date a claimant reasonably discovered a possible connection, product manufacturer, claim type and other facts. Some states apply statutes of repose or special wrongful-death rules.
Estimate Factors Affecting Depo-Provera Settlement Amounts
Use the calculator to organize diagnosis severity, use history, treatment, impairment and economic loss. The result is educational and cannot predict an actual settlement.
Before You Start
- Have approximate injection dates available.
- Know the diagnosis and treatment history.
- Gather major medical expenses and wage loss.
- Treat the output as a planning estimate only.
Primary Sources and Medical Research
Confirmed litigation and labeling statements on this page are based on official federal sources. Peer-reviewed studies are included for medical context, not as individualized medical advice.
JPML Case Count
Pending MDL Dockets by Actions Pending — August 3, 2026
Official federal report listing pending and historical actions in MDL 3140.
Settlement Administrator Order
Appointment of BrownGreer PLC as Settlement Administrator, August 5, 2026.
Case Management Order No. 12
Court order in MDL 3140 issued as the settlement process moved forward.
MDL 3140 Court Page
Northern District of Florida — MDL 3140
Official litigation page, hearing dates, court materials and case information.
Orders by Date
Official source for case-management and pretrial orders, including June 23, 2026 Pretrial Order No. 30A.
FDA Prescribing Information
Depo-Provera CI / depo-subQ provera 104 Label
Federal prescribing information containing meningioma warning and monitoring language.
BMJ Research
Use of Progestogens and Intracranial Meningioma Risk
Peer-reviewed research examining selected progestogens and intracranial meningioma risk.
JAMA Neurology Research
Depot Medroxyprogesterone Acetate and Meningioma
U.S. medical-research context concerning depot medroxyprogesterone acetate exposure.
Frequently Asked Questions About Depo-Provera Settlement Amounts
What is the average Depo-Provera settlement amount?
No reliable average exists. A settlement of a majority of claims was announced on June 15, 2026 and the parties signed a private Master Settlement Agreement on July 21, 2026, but its eligibility criteria and payout matrix have not been made public. Current ranges are TortAdvisor editorial projections, not historical averages.
How much could a severe Depo-Provera meningioma claim be worth?
Illustrative models sometimes place severe, recurrent or permanently disabling claims in a range of $750,000 to $1.5 million or more. This is not a guaranteed payout and an actual outcome could be lower, higher or zero.
Has Pfizer announced a Depo-Provera settlement?
A settlement of a majority of claims in MDL 3140 and related New York litigation was announced on June 15, 2026, and the parties signed a private Master Settlement Agreement on July 21, 2026. Because that agreement is private, no court-approved public payout matrix exists. BrownGreer PLC was appointed Settlement Administrator on August 5, 2026, registration is expected to be completed in November 2026 and payments are expected to begin rolling out by Q1 2027. Claims outside the agreement continue in the active litigation.
How many Depo-Provera lawsuits are pending?
The August 3, 2026 JPML report listed 6,294 pending actions in MDL 3140. Case counts change as actions are filed, transferred, dismissed or resolved.
What evidence is most important?
Injection or pharmacy records, imaging, pathology, neurology records, treatment history, medical bills, wage-loss evidence and a clear use-and-diagnosis timeline are commonly important.
Is the settlement calculator legally binding?
No. The calculator provides an educational estimate based on limited inputs. It does not establish eligibility, create an attorney-client relationship or guarantee compensation.
Will every claimant receive the same amount?
No. Any future settlement may use injury tiers, proof requirements, points, deductions, liens and individual review. Claim values can differ substantially.
Should I wait for a settlement before contacting a lawyer?
No. Filing deadlines may expire before settlement negotiations occur. A lawyer should evaluate the claim and deadline promptly.
Use the Depo-Provera Settlement Amounts Calculator
Estimate a preliminary range based on diagnosis, treatment, injection history, impairment, evidence and economic loss. A licensed attorney must review the facts before providing legal advice.
